PFE Pfizer Inc.

35.45
-0.10  -0%
Previous Close 35.55
Open 35.66
Price To book 3.61
Market Cap 210833523964
Shares 5,947,349,054
Volume 15,617,661
Short Ratio 2.74
Av. Daily Volume 17,306,598

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data presented at ESMO 2017 - Overall survial HR=0.760 (p=0.09)
XALKORI (crizotinib)
ALK-positive advanced non-small cell lung cancer(NSCLC)
Phase 3 data presented at ESMO - risk ratio of 0.940.
PF-05280014
Herceptin biosimilar
Approval announced September 1, 2017.
Mylotarg (gemtuzumab ozogamicin)
Acute myeloid leukemia (AML)
CRL issued June 22, 2017.
Epoetin alfa biosimilar
Phase 3 CROWN trial initiated April 2017.Regulatory filing due 2H 2017.
Lorlatinib
ALK+ NSCLC
Approval announced May 9, 2017.
Avelumab
Urothelial Carcinoma
Approval announced August 17, 2017.
Inotuzumab Ozogamicin
Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults
Phase 3 trial initiated March 2017.
PF-06425090
C. difficile Infection
Phase 3 ongoing. Estimate data 2020 using clinicaltrials.gov data.
XTANDI
Metastatic hormone sensitive prostate cancer
Phase 3 trial terminated - noted May 17, 2017.
XTANDI (ENDEAR)
Triple negative breast cancer
Phase 3 ongoing. Estimate data 1H 2021 using clinicaltrials.gov data.
XTANDI (EMBARK)
Non-metastatic high risk hormone-sensitive prostate cancer
Phase 3 data released September 14, 2017 - primary endpoint met.
XTANDI (PROSPER)
Non-metastatic high risk hormone-sensitive prostate cancer
sNDA acceptance announced July 13, 2017. Exact PDUFA date not released by company. BioPharmCatalyst estimate March 13 using 8-month timeline.
Xeljanz
Ulcerative colitis
PDUFA date December 2017. No exact date given. December 31, 2017 noted as last possible date using guidance of "December 31". Advisory Committee Meeting August 3, 2017 voted 10-1 in favor of recommending approval.
Xeljanz
Psoriatic arthritis
Phase 3 ongoing. Estimate data due late 2017 or early 2018 using clinicaltrials.gov data.
Tanezumab
Chronic low back pain
Phase 3 ongoing. Estimate data due 2018 using clinicaltrials.gov data.
Tanezumab
Cancer pain
Phase 3 ongoing. Estimate data late 2017 or early 2018 using clinicaltrials.gov data.
Tanezumab
Osteoarthritis
Phase 3 data due January 2018.
Talazoparib
BRCA-mutated breast cancer
PDUFA date January 2018. Specific date not released. BPC estimate late January. Advisory Committee Meeting September 19, 2017 voted 6-6 the benefits outweigh risks.
Sutent (Sunitinib)
Renal cell carcinoma (RCC)
Phase 3 trial met primary endpoint - December 2016.
LYRICA (pregabalin)
Pediatric Epilepsy
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP (MOD-4023)
Adults - growth hormone deficiency
Phase 3 initiation announced December 30, 2016.
hGH-CTP (MOD-4023)
Children - growth hormone deficiency
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
Ertugliflozin
Type 2 diabetes
Phase 3 initiated June 2015. Enrollment to be completed 2H 2018.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Phase 3 trial met primary endpoint - December 2016. PDUFA date under priority review for sNDA filing December 2017. Exact date not provided.
BOSULIF
First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Priority review announced November 29, 2016. Approval announced March 23, 2017.
Avelumab
Metastatic Merkel cell carcinoma
sNDA acceptance announced December 21, 2016. Approval announced March 31, 2017.
IBRANCE (palbociclib)
HR+, HER2- Metastatic Breast Cancer

Latest News

  1. Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery
  2. Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
  3. 3 Stocks to Buy with Dividend Yields Above 3%
  4. 3 High-Yield Pharmaceutical Stocks
  5. What Analysts Recommend for Novartis in September 2017
  6. 3 High-Yield Healthcare Stocks
  7. Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear
  8. Neos Therapeutics ADHD Drug Adzenys Receives Approval in US
  9. See what the IHS Markit Score report has to say about Pfizer Inc.
  10. Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
  11. 3 Stocks to Buy and Hold for Decades
  12. Oncology Space in Focus this Week on ESMO Presentations
  13. Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study
  14. Pfizer Punches Back at Johnson & Johnson in Prostate Cancer
  15. Dow Jones Closes at New High
  16. Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO
  17. Markets Right Now: Dow ekes out another high in mixed day
  18. How This Dow Component Could Double Its Prostate-Cancer Market
  19. Dow Posts Fresh Record, Third in a Row, but S&P 500 and Nasdaq Fall